Project Grant K23DK147767
- Federal Project Grant Award Summary Duke University, through its Office of Research Administration, received a $6.29 million Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective August 1, 2025, with a completion date of July 31, 2029. The grant funds a real-world evidence study examining the use of anti-obesity medications (AOMs) in...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases awarded a $1.58 million Project Grant to the University of Kansas Medical Center Research Institute (KUMCRI) on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The project, titled "Changes in Body Composition Including Muscle with Anti-Obesity Medications, Both With and Without Exercise," investigates how...
- Federal Project Grant Award Summary The University of California, San Francisco received a $383,051 Project Grant award dated July 15, 2025, from the National Institute of Diabetes and Digestive and Kidney Diseases under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). This research project, scheduled for completion by March 31, 2030, develops and evaluates a risk communication aid designed to improve medication persistence with sodium glucose cotransporter...
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded $451,000 to The Regents of the University of California, San Francisco under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on September 5, 2025. This Project Grant supports a two-year investigative study (completion date: August 31, 2027) examining the role of microRNAs in adipose tissue dysfunction among people with HIV (PWH) who...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $786,216 Project Grant to the University of California, Los Angeles (UCLA) on August 28, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award supports a four-year research initiative (through June 30, 2029) investigating post-transcriptional regulation of hepatokines and systemic metabolism. The research focuses on identifying...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $167,363 Project Grant to the University of California, Los Angeles, effective March 1, 2026, through February 28, 2031, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The research focuses on identifying novel central nervous system (CNS) mechanisms to combat obesity by investigating how specific neurons in the paraventricular nucleus...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Tufts University School of Medicine a Project Grant of $838,493 on April 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The research is being conducted in Dallas, Texas, with a completion date of February 28, 2031. The project, titled "Optimizing Interventions to Improve Nutrition Security and Reduce Diabetes Risk Among...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded The Johns Hopkins University a $819,091 Project Grant on September 11, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct research on glucose patterns and clinical outcomes in the Dallas Heart Study. The research project, which extends through June 30, 2030, applies continuous glucose monitoring (CGM) systems and novel machine...
- Grant Award Summary The University of Southern California received a Project Grant award of $845,922 from the National Institute of Diabetes and Digestive and Kidney Diseases under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct a longitudinal research study investigating gut-brain pathways in childhood obesity and type 2 diabetes development. The project, initiated March 1, 2026 and scheduled for completion January 31, 2031, will leverage the...
- Federal Grant Award Summary Children's Hospital Los Angeles received a $141,087 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 30, 2025 through April 30, 2027. The award supports basic biomedical research investigating the role of the NGN3 protein in Notch signaling repression during pancreatic endocrinogenesis, with direct...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a Project Grant of $203,244 (awarded May 15, 2026; completion March 31, 2031) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to The Regents of the University of California, San Francisco to conduct the Assessment of Body Composition in Adolescents with Type 2 Diabetes on Glucagon-Like-Peptide Receptor Agonists (GLP-1RAs) study (ABC Study). This clinical research initiative, led by Principal Investigator Dr. Sujatha Seetharaman, focuses on advancing the understanding of how GLP-1 receptor agonist therapy, specifically semaglutide, affects adolescents with type 2 diabetes. The study will deliver empirical research findings addressing critical gaps in pediatric type 2 diabetes treatment by enrolling 50 adolescents (ages 12-17.99 years) and assessing changes in body composition, skeletal muscle mass, functional outcomes, and eating behaviors over a six-month treatment period. Primary research deliverables include quantitative data on fat mass changes via magnetic resonance imaging, skeletal muscle mass measurements using D3 creatine dilution methodology, assessments of muscle quality, strength, and function, correlation analyses between weight loss rates and muscle mass loss, and evaluations of disordered eating risk and weight-related stigma outcomes. The research is expected to optimize treatment safety and efficacy during adolescence and inform clinical decision-making regarding GLP-1 receptor agonist therapy in this vulnerable population.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $203.2k | 5/4/26 |